Study guide

3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens

Key Takeaways Explain This Topic AI

Alcohol withdrawal syndrome (AWS) is an acute excitotoxic emergency driven by the sudden loss of GABAergic inhibition, unrestrained NMDA glutamate receptor excitation, and profound locus coeruleus noradrenergic hyperactivation.

Clinical progression follows a defined timeline: minor withdrawal (6–12 hours: tremors, diaphoresis, insomnia), alcoholic hallucinosis with intact orientation (12–24 hours), generalized tonic-clonic withdrawal seizures (24–48 hours), and Delirium Tremens (48–96 hours: fluctuating delirium, severe autonomic storm, 1–5% mortality).

The CIWA-Ar (10 items, maximum score 67) categorizes withdrawal as mild (<10), moderate (10–18), or severe (≥19); symptom-triggered benzodiazepine protocols (e.g., diazepam 10–20 mg or chlordiazepoxide 50–100 mg for CIWA ≥10) reduce total drug exposure and treatment duration compared to fixed-dose tapers.

In patients with hepatic impairment, cirrhosis, or advanced age, oxidative Phase I CYP450 metabolism is compromised; the 'LOT' benzodiazepines (Lorazepam, Oxazepam, Temazepam) undergo direct Phase II glucuronidation and are strictly mandatory to avoid toxic accumulation and hepatic encephalopathy.

Refractory alcohol withdrawal (requiring >50 mg IV diazepam or >10 mg IV lorazepam in 1–2 hours) reflects GABA depletion and receptor uncoupling; IV Phenobarbital rescue protocols act directly on barbiturate sites to prolong chloride channel opening independently of GABA and inhibit excitatory AMPA receptors.

Last updated: September 2026

3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepines & Delirium Tremens

Quick Answer: Acute alcohol withdrawal is a life-threatening excitotoxic crisis caused by the sudden loss of inhibitory GABA-A tone combined with unrestrained NMDA glutamate receptor excitation and massive noradrenergic surge from the locus coeruleus. The CIWA-Ar scale guides therapy: scores < 10 <10 < 10 require supportive care, while scores ≥ 10 \ge 10 ≥ 10 mandate pharmacotherapy. Symptom-triggered regimens using long-acting benzodiazepines (diazepam 10–20 mg or chlordiazepoxide 50–100 mg) represent the gold standard in monitored environments. However, in patients with hepatic failure, cirrhosis, or advanced age , the " LOT " benzodiazepines ( Lorazepam , Oxazepam , Temazepam ) are strictly required because they bypass Phase I CYP450 oxidation and undergo direct Phase II glucuronidation. In cases of severe, benzodiazepine-refractory withdrawal, intravenous phenobarbital serves as the definitive rescue agent.

1. Pathophysiology of Alcohol Withdrawal: The Excitotoxic Surge

Acute Alcohol Withdrawal Syndrome (AWS) represents an abrupt rebound neurochemical storm triggered when chronic ethanol intake is suddenly curtailed or eliminated:

Acute Loss of GABAergic Inhibition: The brain's downregulated, conformationally uncoupled GABA-A receptors are suddenly deprived of ethanol's positive allosteric support. Endogenous GABA is insufficient to maintain baseline inhibitory chloride currents, leading to immediate neuronal disinhibition.

Unrestrained NMDA Excitotoxicity: The upregulated, hypersensitized NMDA receptor population (specifically GluN1/GluN2B subunits) and voltage-dependent calcium channels are freed from ethanol-mediated uncompetitive antagonism. Ambient extracellular glutamate binds to these hyperabundant receptors, triggering an unchecked influx of calcium ( C a 2 + Ca^{2+} C a 2 + ) and sodium ( N a + Na^+ N a + ). This produces post-synaptic hyperexcitability, generation of reactive oxygen species (ROS), calpain activation, mitochondrial injury, and potential apoptotic neuronal death.

Locus Coeruleus Noradrenergic Hyperactivity: Glutamatergic stimulation of the locus coeruleus in the dorsal pons provokes massive, unrestrained release of norepinephrine and epinephrine into central pathways and the peripheral sympathetic nervous system. This adrenergic storm drives the classic peripheral autonomic manifestations of AWS: severe diaphoresis, tachycardia, systolic hypertension, mydriasis, motor restlessness, and severe tremors.

The Kindling Hypothesis: Repeated, sequential episodes of medically unmanaged or poorly managed alcohol withdrawal lead to progressive electrophysiological neurosensitization ("kindling"). Each untreated withdrawal episode lowers the seizure threshold, accelerates the onset of subsequent withdrawal episodes, enhances cognitive impairment, and increases the lifetime vulnerability to Delirium Tremens.

2. Clinical Progression Timeline & Withdrawal Staging

Alcohol withdrawal unfolds across a predictable clinical continuum based on the time elapsed since the last drink (or since blood alcohol concentration drops below the individual's physiological tolerance threshold): Hours Post-Cessation:

  • 0h 6h 12h 24h 48h 72h 96h
  • ├───────────┼───────────┼───────────┼───────────┼───────────┼───────────┤
  • ▲ ▲ ▲ ▲
  • │ │ │ └─ Delirium Tremens (48-96h)
  • │ │ └─ Withdrawal Seizures (24-48h)
  • │ └─ Alcoholic Hallucinosis (12-24h)
  • └─ Minor Autonomic Withdrawal (6-12h)
  • Stage 1: Minor Withdrawal (6 to 12 Hours Post-Cessation)

Pathophysiology: Initial central and peripheral noradrenergic hyperactivity.

Manifestations: Coarse postural tremor of outstretched hands and tongue, diaphoresis, resting tachycardia ( H R > 100 bpm HR > 100\text{ bpm} H R > 100 bpm ), systolic hypertension, nausea, anorexia, headache, severe insomnia, internal restlessness, and anxiety.

Clinical Note: Symptoms can emerge while the patient still has a positive blood alcohol level (BAL) if the concentration has fallen significantly below their adapted baseline.

Stage 2: Alcoholic Hallucinosis (12 to 24 Hours Post-Cessation)

Pathophysiology: Transient cortical sensory disinhibition without generalized encephalopathy.

Manifestations: Perceptual distortions and vivid hallucinations that are most commonly visual (e.g., seeing insects, small animals, shadowing), but may be auditory (voices, clicking, ringing) or tactile (formication, feeling bugs crawling on skin).

CRITICAL ADVANCED PRACTICE DISTINCTION: In alcoholic hallucinosis, the patient has a clear sensorium and intact orientation to person, place, and time. Patients frequently exhibit preserved insight, stating they recognize the hallucinations are not real. This is NOT Delirium Tremens and must not be confused with primary psychosis or delirium.

Stage 3: Alcohol Withdrawal Seizures (24 to 48 Hours Post-Cessation)

Pathophysiology: Severe subcortical and cortical neuronal hyperexcitability and sudden loss of seizure threshold.

Manifestations: Sudden-onset, generalized tonic-clonic (GTC) seizures . Seizures typically occur in brief bursts or clusters (1 to 3 discrete seizures within a 6-hour window). Interictal electroencephalograms (EEGs) are normal.

Status Epilepticus Risk: Progresses to status epilepticus in approximately 3% of untreated cases.

Pharmacological Pearl: Classic antiepileptic drugs (e.g., phenytoin , levetiracetam) are completely ineffective for the prevention or acute arrest of alcohol withdrawal seizures because the underlying mechanism is not a focal epileptic focus but acute GABA/NMDA allosteric imbalance. Benzodiazepines are the absolute first-line treatment and prevention.

Stage 4: Delirium Tremens (DTs) (48 to 96 Hours Post-Cessation)

Pathophysiology: Catastrophic, widespread neurochemical collapse, profound sympathovagal failure, and cortical metabolic exhaustion.

Clinical Manifestations:

Fluctuating Delirium: Marked clouding of consciousness, severe global disorientation, acute memory loss, and profound cognitive fragmentation.

Severe Autonomic Hyperactivity: Hyperpyrexia (fever > 38.5 ∘ C >38.5^\circ\text{C} > 38. 5 ∘ C without occult infection), malignant tachycardia ( H R > 120 – 140 bpm HR > 120\text{–}140\text{ bpm} H R > 120 – 140 bpm ), severe labile hypertension, drenching diaphoresis, and tachypnea.

Terrifying Perceptual Chaos: Intense, florid visual hallucinations (zoopsia—seeing terrifying beasts or insects), tactile hallucinations, paranoia, and severe, combative psychomotor agitation.

Mortality & Prognosis: Without aggressive medical intervention, mortality historically approached 20% to 35%. Modern intensive care and protocolized IV sedation have reduced mortality to 1% to 5% , with deaths primarily resulting from hyperthermia, cardiac arrhythmias, circulatory collapse, or aspiration pneumonitis.

Summary of Withdrawal Stages

Stage Peak Onset Clinical Hallmarks Mental Status / Sensorium First-Line Management

Minor Withdrawal 6–12 hrs Tremor, sweating, insomnia, tachycardia, nausea Clear, oriented, anxious CIWA-Ar scoring; supportive care; oral benzodiazepines if CIWA ≥ 10 \ge 10 ≥ 10

Alcoholic Hallucinosis 12–24 hrs Visual, auditory, or tactile hallucinations Clear sensorium; fully oriented ; insight intact Symptom-triggered benzodiazepines; calm, well-lit environment

Withdrawal Seizures 24–48 hrs Generalized tonic-clonic seizures (single or brief cluster) Post-ictal somnolence, otherwise normal IV Diazepam or Lorazepam; avoid phenytoin; ICU monitoring

Delirium Tremens 48–96 hrs Encephalopathy, profound autonomic storm, fever, agitation Delirious, disoriented , fluctuating consciousness High-dose parenteral benzodiazepines / phenobarbital; ICU admission

3. Risk Stratification for Complicated Withdrawal & Delirium Tremens

Identifying high-risk individuals prior to clinical decompensation allows the APRN to order preemptive inpatient admission, aggressive prophylactic pharmacotherapy, and intensive care monitoring.

Major Risk Factors for Delirium Tremens and Complicated Withdrawal

Prior History of Complicated Withdrawal: A documented personal history of withdrawal seizures or Delirium Tremens is the single strongest independent predictor of future DTs due to the kindling phenomenon.

High Level of Recent Alcohol Consumption: Sustained daily intake exceeding 150 – 200 g 150\text{–}200\text{ g} 150 – 200 g of pure ethanol (equivalent to a pint of distilled spirits, 1.5 bottles of wine, or 10–12 high-gravity beers daily) for months to years.

Advanced Age ( > 65 >65 > 65 Years): Decreased neuronal reserve, altered pharmacokinetics, and diminished organ function.

Significant Co-Occurring Acute Medical/Surgical Illness: Sepsis, severe pneumonia, acute pancreatitis, rib fractures, intracranial trauma, or acute gastrointestinal hemorrhage markedly increase metabolic demand and precipitate DTs.

Initial Severe Autonomic Instability: Presenting to triage with a CIWA-Ar score ≥ 15 – 20 \ge 15\text{–}20 ≥ 15 – 20 , persistent tachycardia ( H R > 120 bpm HR > 120\text{ bpm} H R > 120 bpm ), or marked systolic hypertension.

Marked Laboratory Abnormalities: Presence of hypokalemia ( K + < 3.5 mEq/L K^+ < 3.5\text{ mEq/L} K + < 3.5 mEq/L ), hypomagnesemia ( M g 2 + < 1.5 mg/dL Mg^{2+} < 1.5\text{ mg/dL} M g 2 + < 1.5 mg/dL ), elevated baseline blood alcohol concentration ( > 0.20 g/dL >0.20\text{ g/dL} > 0.20 g/dL ) while already exhibiting prominent withdrawal symptoms, or severe thrombocytopenia ( < 100 , 000 / μ L <100,000/\mu\text{L} < 100 , 000/ μ L ). Elevated baseline transaminases and homocysteine also correlate with increased seizure risk.

4. Assessment with the CIWA-Ar Protocol

The Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar) is the internationally validated, 10-item clinician-administered assessment scale utilized to quantify withdrawal severity and drive medication titration.

The 10 CIWA-Ar Clinical Items

Each item is scored from 0 to 7 (except Orientation, which is scored 0 to 4):

Nausea and Vomiting (0–7): 0 = none 0 = \text{none} 0 = none ; 1 = mild nausea, no vomiting 1 = \text{mild nausea, no vomiting} 1 = mild nausea, no vomiting ; 4 = intermittent nausea with dry heaves 4 = \text{intermittent nausea with dry heaves} 4 = intermittent nausea with dry heaves ; 7 = constant nausea, frequent dry heaves, and vomiting 7 = \text{constant nausea, frequent dry heaves, and vomiting} 7 = constant nausea, frequent dry heaves, and vomiting .

Tremor (0–7): Evaluated with arms extended and fingers spread. 0 = no tremor 0 = \text{no tremor} 0 = no tremor ; 1 = not visible, but felt fingertip to fingertip 1 = \text{not visible, but felt fingertip to fingertip} 1 = not visible, but felt fingertip to fingertip ; 4 = moderate, visible with arms extended 4 = \text{moderate, visible with arms extended} 4 = moderate, visible with arms extended ; 7 = severe, visible even without arms extended 7 = \text{severe, visible even without arms extended} 7 = severe, visible even without arms extended .

Paroxysmal Sweats (0–7): 0 = no sweat 0 = \text{no sweat} 0 = no sweat ; 1 = barely perceptible palms 1 = \text{barely perceptible palms} 1 = barely perceptible palms ; 4 = beads of sweat obvious on forehead 4 = \text{beads of sweat obvious on forehead} 4 = beads of sweat obvious on forehead ; 7 = drenching sweats 7 = \text{drenching sweats} 7 = drenching sweats .

Anxiety (0–7): 0 = no anxiety 0 = \text{no anxiety} 0 = no anxiety ; 1 = mildly anxious 1 = \text{mildly anxious} 1 = mildly anxious ; 4 = moderately anxious, guarded 4 = \text{moderately anxious, guarded} 4 = moderately anxious, guarded ; 7 = acute panic state 7 = \text{acute panic state} 7 = acute panic state .

Agitation (0–7): 0 = normal activity 0 = \text{normal activity} 0 = normal activity ; 1 = somewhat more than normal activity 1 = \text{somewhat more than normal activity} 1 = somewhat more than normal activity ; 4 = moderately fidgety and restless 4 = \text{moderately fidgety and restless} 4 = moderately fidgety and restless ; 7 = paces back and forth, thrashes about 7 = \text{paces back and forth, thrashes about} 7 = paces back and forth, thrashes about .

Tactile Disturbances (0–7): Assesses itching, pins/needles, burning, numbness, or formication. 0 = none 0 = \text{none} 0 = none ; 1 = very mild itch/numbness 1 = \text{very mild itch/numbness} 1 = very mild itch/numbness ; 4 = moderate hallucinations/crawling sensations 4 = \text{moderate hallucinations/crawling sensations} 4 = moderate hallucinations/crawling sensations ; 7 = continuous severe tactile hallucinations 7 = \text{continuous severe tactile hallucinations} 7 = continuous severe tactile hallucinations .

Auditory Disturbances (0–7): Assesses auditory sharpness or hallucinations. 0 = not present 0 = \text{not present} 0 = not present ; 1 = mild harshness/startle 1 = \text{mild harshness/startle} 1 = mild harshness/startle ; 4 = moderate hallucinations 4 = \text{moderate hallucinations} 4 = moderate hallucinations ; 7 = continuous terrifying auditory hallucinations 7 = \text{continuous terrifying auditory hallucinations} 7 = continuous terrifying auditory hallucinations .

Visual Disturbances (0–7): Assesses photophobia or visual hallucinations. 0 = none 0 = \text{none} 0 = none ; 1 = mild sensitivity to light 1 = \text{mild sensitivity to light} 1 = mild sensitivity to light ; 4 = moderate hallucinations 4 = \text{moderate hallucinations} 4 = moderate hallucinations ; 7 = continuous terrifying visual hallucinations 7 = \text{continuous terrifying visual hallucinations} 7 = continuous terrifying visual hallucinations .

Headache, Fullness in Head (0–7): 0 = none 0 = \text{none} 0 = none ; 1 = very mild 1 = \text{very mild} 1 = very mild ; 4 = moderate 4 = \text{moderate} 4 = moderate ; 7 = severe, pounding 7 = \text{severe, pounding} 7 = severe, pounding .

Orientation and Clouding of Sensorium (0–4): 0 = oriented to person, place, date 0 = \text{oriented to person, place, date} 0 = oriented to person, place, date ; 1 = uncertain about date or 1–2 days off 1 = \text{uncertain about date or 1–2 days off} 1 = uncertain about date or 1–2 days off ; 2 = disoriented to date by >2 days 2 = \text{disoriented to date by >2 days} 2 = disoriented to date by >2 days ; 3 = disoriented to place or person 3 = \text{disoriented to place or person} 3 = disoriented to place or person ; 4 = completely disoriented 4 = \text{completely disoriented} 4 = completely disoriented .

  • Maximum Possible Score: 67 points
  • Scoring Tiers & Action Algorithm

< 10 <10 < 10 (Mild Withdrawal): Non-pharmacological supportive care, quiet environment, oral hydration, parenteral thiamine, frequent reassessment every 4 to 6 hours.

10 to 18 (Moderate Withdrawal): Indication for active pharmacotherapy (symptom-triggered benzodiazepine dosing); reassess hourly or every 2 hours until score < 10 <10 < 10 .

≥ 19 \ge 19 ≥ 19 (Severe Withdrawal): High risk for seizures, aspiration, and Delirium Tremens. Requires aggressive parenteral pharmacotherapy, continuous telemetry, intensive nursing observation, and consideration for ICU transfer.

Caution

Critical Limitations of CIWA-Ar: The CIWA-Ar is completely invalid in patients who are non-verbal, endotracheally intubated, comatose, or severely delirious and unable to respond reliably to subjective queries (e.g., headache, nausea, tactile sensations). In such patients, validated objective sedation-agitation scales such as the Richmond Agitation-Sedation Scale (RASS) or Minnesota Detoxification Scale (mSAS) must be used instead.

5. Symptom-Triggered vs. Fixed-Dose Benzodiazepine Protocols

Benzodiazepines remain the evidence-based first-line class for preventing withdrawal seizures and mitigating autonomic hyperactivity by binding to the allosteric benzodiazepine site on GABA-A receptors, enhancing chloride channel opening frequency in the presence of GABA.

Symptom-Triggered Dosing (Gold Standard)

In a symptom-triggered regimen , medication is administered only when clinical assessment indicates active withdrawal (typically defined as a CIWA-Ar score ≥ 10 \ge 10 ≥ 10 or ≥ 8 \ge 8 ≥ 8 depending on institution):

Standard Protocol: Evaluate CIWA-Ar every 1 to 2 hours. If CIWA-Ar ≥ 10 \ge 10 ≥ 10 , administer:

Diazepam: 10 to 20 mg 10\text{ to }20\text{ mg} 10 to 20 mg PO (or 5 to 10 mg 5\text{ to }10\text{ mg} 5 to 10 mg IV slowly),

OR Chlordiazepoxide: 50 to 100 mg 50\text{ to }100\text{ mg} 50 to 100 mg PO.

Recheck CIWA-Ar in 60 minutes. If still ≥ 10 \ge 10 ≥ 10 , repeat dose. Once score remains < 10 <10 < 10 on consecutive checks, lengthen assessment intervals to every 4 to 6 hours.

Clinical Superiority (Evidence-Based): Landmark prospective randomized trials (e.g., Saitz et al.) demonstrated that compared to fixed-schedule tapers, symptom-triggered therapy results in:

Marked reduction in total benzodiazepine requirement (often > 60 % >60\% > 60% reduction, e.g., median 100 mg 100\text{ mg} 100 mg vs 425 mg 425\text{ mg} 425 mg chlordiazepoxide equivalent),

Dramatically shortened duration of treatment (median ∼ 9 hours \sim 9\text{ hours} ∼ 9 hours vs ∼ 68 hours \sim 68\text{ hours} ∼ 68 hours ),

Significantly lower rates of oversedation, respiratory depression, and iatrogenic delirium .

Fixed-Dose Taper Regimen

A fixed-dose regimen delivers scheduled benzodiazepine doses at predetermined intervals around the clock, tapering over 3 to 7 days (e.g., chlordiazepoxide 50 mg 50\text{ mg} 50 mg PO q6h for 24 hours, then 25 mg 25\text{ mg} 25 mg PO q6h for 24 hours, then 25 mg 25\text{ mg} 25 mg PO q12h for 24 hours, with PRN doses for breakthrough CIWA ≥ 10 \ge 10 ≥ 10 ):

Indications:

  • Outpatient detoxification settings where continuous nursing reassessment is unavailable,
  • Inpatient units with high patient-to-nurse ratios where hourly CIWA-Ar scoring cannot be guaranteed,

Patients with a confirmed history of sudden, severe withdrawal seizures or DTs who may experience explosive seizures before escalating CIWA-Ar scores trigger a PRN dose.

Pharmacokinetics of First-Line Long-Acting Benzodiazepines

In patients with normal hepatic function, long-acting agents are strongly preferred because their active metabolites provide a smooth, self-tapering "pharmacological buffer" that prevents rebound withdrawal spikes:

Diazepam (Valium): Extremely rapid onset of action (lipid-soluble, enters CNS within 5–15 minutes), ideal for rapid acute symptom control. Elimination half-life of parent drug is 20–50 hours, but active hepatic oxidation metabolite desmethyldiazepam (nordiazepam) has an elimination half-life of up to 100+ hours .

Chlordiazepoxide (Librium): Slower oral onset (30–90 minutes), providing smooth, steady symptom management with less initial euphoria. Metabolized via hepatic oxidation to multiple active intermediates (demoxepam, desoxydiazepam) with extended half-lives.

6. Hepatic Impairment & The "LOT" Benzodiazepine Rule

In patients with advanced liver disease, cirrhosis, alcoholic hepatitis, or acute hepatic decompensation, the pharmacokinetic profile of standard benzodiazepines changes dramatically and can be catastrophic.

The Mechanism of Hepatic Toxicity

Phase I Hepatic Metabolism (CYP450 Oxidation): Diazepam and chlordiazepoxide depend completely on hepatic Cytochrome P450 (CYP3A4, CYP2C19) microsomal oxidation. In cirrhotic or severely inflamed liver tissue, Phase I enzyme systems are severely impaired. Administering diazepam or chlordiazepoxide leads to massive, unpredictable drug accumulation , profound prolonged sedation, respiratory arrest, and precipitation of hepatic encephalopathy that can mimic or worsen Delirium Tremens.

Phase II Hepatic Metabolism (Glucuronidation): In contrast, Phase II direct glucuronidation conjugation pathways remain remarkably preserved even in advanced cirrhosis and liver failure.

The "LOT" Benzodiazepines

The mnemonic "LOT" identifies the three benzodiazepines that bypass Phase I oxidation entirely and are metabolized exclusively by direct Phase II glucuronidation :

  • L — Lorazepam (Ativan)
  • O — Oxazepam (Serax)
  • T — Temazepam (Restoril) [Hepatic Metabolism Pathway]
  • Diazepam / Chlordiazepoxide ──► [Phase I CYP450 Oxidation] (Blunted in Cirrhosis!)
  • │
  • ▼ (Active Metabolite Accumulation)
  • Hepatic Encephalopathy / Coma
  • "LOT" Agents (Lorazepam) ──► [Phase II Glucuronidation] (Preserved in Cirrhosis!)
  • │
  • ▼ (Inactive Glucuronide Conjugate)
  • Safe Renal Excretion
  • Advanced Practice Clinical Selection

Lorazepam (Ativan): The universal gold standard for alcohol withdrawal in patients with hepatic impairment, advanced age ( > 65 >65 > 65 ), acute respiratory failure, or uncertain liver function. Available in both oral and parenteral (IV/IM) formulations. Elimination half-life is 10 to 20 hours with no active metabolites .

Dosing: 1 to 2 mg 1\text{ to }2\text{ mg} 1 to 2 mg PO/IV (or up to 4 mg 4\text{ mg} 4 mg IV in severe cases) every 1 to 2 hours symptom-triggered for CIWA-Ar ≥ 10 \ge 10 ≥ 10 .

Oxazepam (Serax): Oral-only agent with slow gastrointestinal absorption. Effective for mild-to-moderate outpatient withdrawal in liver disease ( 15 to 30 mg 15\text{ to }30\text{ mg} 15 to 30 mg PO q6–8h PRN), but inappropriate for acute emergency sedation due to delayed onset.

  • 7. Refractory Alcohol Withdrawal & Phenobarbital Rescue Protocols
  • Defining Refractory Alcohol Withdrawal

Refractory alcohol withdrawal occurs when a patient continues to exhibit severe, escalating withdrawal (e.g., persistent CIWA-Ar > 15 – 20 >15\text{–}20 > 15 – 20 , malignant tachycardia, severe delirium) despite receiving massive doses of benzodiazepines—defined by the American Society of Addiction Medicine (ASAM) as requiring > 50 mg >50\text{ mg} > 50 mg of IV diazepam (or > 10 mg >10\text{ mg} > 10 mg of IV lorazepam ) within the first 1 to 2 hours of treatment.

The Neurochemical Basis of Benzodiazepine Resistance

Why do high doses of benzodiazepines fail in severe withdrawal?

Obligatory GABA Requirement: Benzodiazepines are pure allosteric modulators; they do not open chloride channels directly . They only increase the frequency of channel opening in the presence of endogenous GABA.

GABA Depletion: In prolonged severe alcohol withdrawal, presynaptic GABA stores are depleted, leaving benzodiazepines without a substrate to exert their physiological effect.

Receptor Uncoupling: Severe neuroadaptation causes structural uncoupling between the GABA-A receptor and its benzodiazepine binding site, rendering the channel refractory to benzodiazepine modulation.

Phenobarbital Pharmacology & Superiority

Phenobarbital (a long-acting barbiturate) overcomes all cellular mechanisms of benzodiazepine failure:

Independent Channel Gating: Phenobarbital binds to a distinct allosteric site on the GABA-A receptor and increases the duration (dwell time) of chloride channel opening. At higher concentrations, barbiturates can directly gate and open the chloride channel independently of endogenous GABA .

AMPA / Kainate Receptor Antagonism: Phenobarbital concurrently acts as an antagonist at non-NMDA (AMPA and kainate) glutamate receptors, directly suppressing glutamatergic excitotoxicity.

Pharmacokinetics: Has an elimination half-life of 80 to 120 hours , providing an automatic, smooth "auto-taper" that eliminates rebound withdrawal once loaded.

Evidence-Based Phenobarbital Protocols

Intravenous Loading Protocol (ICU / Emergency Step-down): Administer an initial weight-based loading dose of 10 mg/kg 10\text{ mg/kg} 10 mg/kg IV infused over 30 minutes in normal saline (or boluses of 130 to 260 mg 130\text{ to }260\text{ mg} 130 to 260 mg IV every 15 to 30 minutes) titrated to achieve light somnolence or symptom control (RASS − 1 -1 − 1 to 0 0 0 , CIWA < 10 <10 < 10 ), up to a cumulative maximum of 15 to 20 mg/kg 15\text{ to }20\text{ mg/kg} 15 to 20 mg/kg .

Clinical Outcomes: Protocolized phenobarbital administration has been shown in intensive care trials to dramatically reduce ICU length of stay, decrease the need for mechanical ventilation, and rapidly abort benzodiazepine-resistant Delirium Tremens.

Safety Monitoring: Continuous pulse oximetry, cardiac telemetry, blood pressure monitoring, and bedside availability of airway/suction equipment are mandatory due to the risk of synergistic respiratory depression when combined with prior benzodiazepines.